CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D005221: Fatigue NIH

(Synonyms: Fatigue)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (8)


Name (Synonyms) Correlation
drug3211 blood test Wiki 0.58
drug3165 actigraphy Wiki 0.58
drug45 40mg of MitoQ Wiki 0.58
drug1693 Maximal effort test Wiki 0.58
drug1856 Neuromuscular evaluation Wiki 0.58
drug25 20 mg MitoQ Wiki 0.58
drug2322 Questionnaires Wiki 0.24
drug2122 Placebo Wiki 0.03

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D015673 Fatigue Syndrome, Chronic NIH 0.41
D012598 Scoliosi NIH 0.35
D009103 Multiple Sclerosis NIH 0.33

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0012378 Fatigue HPO 1.00

There are 3 clinical trials

Clinical Trials


1 MitoQ for Fatigue in Multiple Sclerosis: A Placebo Controlled Trial

The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after drug initiation will assess if MitoQ has a significant change in fatigue.

NCT04267926 Multiple Sclerosis Fatigue Drug: 20 mg MitoQ Drug: Placebo Drug: 40mg of MitoQ
MeSH:Multiple Sclerosis Sclerosis Fatigue
HPO:Fatigue

Primary Outcomes

Description: MFIS is a self -reported fatigue survey. Scale 0 - 84

Measure: Modified Fatigue Inventory Scale (MFIS)

Time: 12 weeks

Secondary Outcomes

Description: SDMT measures cognitive function. Scale 0-110

Measure: Symbol Digit Modalities Test (SDMT)

Time: 12 weeks

Description: EDSS measures neurological function. Scale 0-10

Measure: Expanded Disability Status Scale (EDSS)

Time: 12 weeks

Description: BDI is a self-reported questionnaire measuring depression. Scale 0-21

Measure: Beck's Depression Inventory (BDI)

Time: 12 weeks

2 Chronic Fatigue Etiology and Recovery in Covid-19 Patients in Intensive Care Unit : the Role of Fatigability

Chronic fatigue is the most common and debilitating symptom in intensive care unit (ICU) survivors. Indeed, it has been widely reported that patients who stayed in ICU for prolonged periods report a feeling of tiredness for months to years after ICU discharge. This symptom seems particularly pronounced in Covid-19 patients and may affect their quality of life by decreasing their capacity to perform simple tasks of daily life. The aim of the present project is to determine whether deteriorated neuromuscular function (i.e. increased fatigability) is involved in the feeling of fatigue of Covid-19 patients. Because the causes of this feeling are multi-dimensional, a large battery of tests will allow us to better understand the origin of chronic fatigue. A better knowledge of chronic fatigue etiology and its recovery will allow to optimize rehabilitation treatments to shorten the persistence of chronic fatigue and in fine improve life quality.

NCT04363606 Chronic Fatigue Syndrome Intensive Care Unit Muscle Other: Questionnaires Biological: blood test Other: Maximal effort test Device: actigraphy Device: Neuromuscular evaluation
MeSH:Fatigue Syndrome, Chronic Fatigue
HPO:Fatigue

Primary Outcomes

Measure: voluntary maximum force reduction

Time: 6 weeks post-discharge

Secondary Outcomes

Description: Level of cortical activation and cortico-spinal excitability measured by transcranial magnetic stimulation

Measure: Neuromuscular function : cortical activity

Time: 6 weeks post-discharge

Description: Peripheral function by electrical nerve stimulation

Measure: Neuromuscular function : Peripheral function

Time: 6 weeks post-discharge

Description: measured by effort test

Measure: Maximal oxygen uptake (VO2max)

Time: 6 weeks post-discharge

Description: measured by actigraphy

Measure: quality of sleep

Time: 6 weeks post-discharge

Description: with Magnetic resonance imaging

Measure: muscle volume

Time: 6 weeks post-discharge

Description: measured by a Phosphorus 31 Nuclear magnetic resonance test

Measure: metabolic fatigue

Time: 6 weeks post-discharge

3 Investigation of Fatigue, Physical Activity, Sleep Quality and Anxiety Levels of Multiple Sclerosis Patients in the COVID-19 Pandemic

Hundreds of thousands of confirmed cases have been reported worldwide, just 3 months after the first patients were identified in Wuhan, China. Just like other members of the community, MS patients are uncomfortable with the emotional distress and health anxiety caused by the COVID-19 outbreak. Most MS patients receive immunosuppressive or immunomodulatory therapies. Patients taking immunosuppressive agents are theoretically at increased risk of being affected by viral pandemics, and a higher health concern is expected in this group of patients. Moreover, MS patients lose social support. Patients with increased duration of stay can no longer access physical and cognitive rehabilitation therapies. We also know that increased anxiety and sleep disorders can cause MS patients to have an attack. When literature is examined, it is known that MS patients' physical activity levels decrease, fatigue, sleep quality and anxiety levels increase, so their quality of life and participation in daily life activities decrease. MS patients lose social support during the COVID-19 outbreak. For all these reasons, we think that the fatigue, physical activity level, anxiety level and sleep disturbances affected before the COVID-19 outbreak will be further affected for these reasons.

NCT04438954 Multiple Sclerosis Covid-19
MeSH:Multiple Sclerosis Sclerosis Fatigue
HPO:Fatigue

Primary Outcomes

Description: Fatigue was assessed by the Fatigue Severity Scale (FSS). This is a 9‐item questionnaire that assesses the effect of fatigue on daily living. Each item is a statement on fatigue that the subject rates from 1 "completely disagree" to 7 "completely agree". A score of 4 or higher generally indicates severe fatigue

Measure: Fatigue

Time: 4 week

Description: Physical activity levels were assessed by the International Physical Activity Questionnaire (IPAQ): short form. The online self-reporting questionnaire consisted of questions investigating the respondents' PA practice in terms of frequencies and durations of sitting, walking, moderate-intensity physical activities and vigorous-intensity physical activities. The MET-minutes per week (MET-min/week) were calculated using the following formula: intensity (MET) x duration x frequency. Physical activity levels were classified as physically inactive (<600 MET-min/week), with low levels of physical activity (600-3000 MET- min/week) and physical activity level that is sufficient (> 3000 MET-min/week)

Measure: Physical activity

Time: 4 week

Description: The Pittsburgh Sleep Quality Index (PSQI) questionnaire was used to measure sleep quality using an 18-item scale containing seven items that included sleep quality, sleep duration, sleep latency, habitual sleep efficiency, sleep disturbance, use of sleeping medications, and daytime dysfunction. Each dimension scored between 0-3, with a total score ranging from 0-21, and a higher score indicating lower sleep quality.

Measure: Sleep quality

Time: 4 week

Description: The Hospital Anxiety and Depression Scale (HADS) was composed by two subscales (i.e., anxiety and depression), with 7-items each. The anxiety part of HADS was used to evaluate the anxiety levels of the patients. Each dimension scored between 0-3, with a total score ranging from 0-21, and a higher score indicating higher anxiety level.

Measure: Anxiety

Time: 4 week


HPO Nodes


HP:0012378: Fatigue
Genes 398
PFN1 SOX3 ATRX VHL LBR BIRC3 BLNK GNAS CD79A SH2B3 STAT5B EPCAM NF1 MEFV IL12A-AS1 CTLA4 MLX PON1 PNPLA8 RPL5 RUNX1 KCNQ1 RRM2B GPR35 ELANE PPARGC1A IGH GLA DBH CCR1 MLH3 XPC MSH2 CCND1 KLRC4 ATP7A KCNQ3 PSTPIP1 PALLD HLA-B TCF4 CDKN2A RUNX1 BCOR ALB AGK GBA NEK1 CFI IRF2BP2 ALAS2 MRAP OPTN MYD88 CAV3 NKX2-1 BCL2 CCDC78 PALB2 C9ORF72 UNC13A DNAJC6 SDHA SMAD4 TBX19 C4A ATM PDE8B RPS28 NUMA1 SCN8A MMACHC NFKB2 PRKAR1A MST1 HBA1 RPL11 SOX3 SLC25A11 SCNN1A ERBB4 UBQLN2 SLC18A3 PODXL HFE SQSTM1 ARMC5 HLA-DPB1 PRRT2 MET NPM1 SLC26A4 NAGS FAS CCNF TSHR STAR SDHD IL12A SPIB PREPL RET POU1F1 WIPF1 DLST LHX4 TSC1 HNF1A TET2 DCTN1 STEAP3 FOXE1 TREM2 NABP1 FGFR1 PYGM HESX1 WAS SLC5A5 INSR NEFH KCNN4 IL23R SOD1 HESX1 ERAP1 RPS27 RPS7 FOXP1 STAT6 CALR CFH DMPK DUOX2 BRCA1 VCP TARDBP GCK DYSF TBL1XR1 CCND1 MSH6 PMS1 COL1A2 ACADM BCR SDHB IGLL1 MEN1 EPOR PRTN3 UNC93B1 MDH2 DNMT3A HLA-B BRCA2 JAK2 HMGCL DDB2 RPS17 CHMP2B CFAP410 IL12RB1 PAX8 LHX4 CPT1A ERCC2 RPL35A MMEL1 RPS20 PRKACA COL5A2 RET RPL31 PYGL RPL15 IRF5 NKX2-5 HLA-DRB1 EPHA4 ABL1 ERCC4 RPL27 DNM1L SLC25A4 SMAD3 POU1F1 HAVCR2 OPA1 PLEC SLC26A4 JAK2 KCNE1 CBL SDHB KIT ATP13A2 RPS24 PGM1 DAO GATA1 NAB2 SDHB SDHAF2 VHL DMD PDGFRA PMS2 ALB ERCC5 SLC11A1 PON2 CPT2 IGHM RPS26 PROP1 PML PIGT AP2S1 SCNN1B HNRNPA1 SLC18A2 PROP1 TSHR POMGNT1 COQ2 RPL26 RPS29 SDHC MALT1 SDHD HESX1 FUS SDHC FH SCN2A GLE1 C1QBP GPR101 LHX3 MATR3 RPS10 CPT2 PON3 CHRND BCL10 BCL6 ZBTB16 AIP GLT8D1 TAZ TGFBR2 KRAS SERPINA6 HLA-B TWNK IKZF1 UBAC2 ABCC2 RARA MORC2 MYH7 ANXA11 POLG EPAS1 CDH23 SLC2A10 PTPN22 TFR2 SEMA4A POLG2 GCH1 PROKR2 KCNQ2 TLR3 TAF15 TRAF3 FIP1L1 ASXL1 CDC73 SOX2 TNPO3 ATXN2 TXNRD2 TRNK HLA-DPA1 LRRC8A MPL TSC2 DUOXA2 TLR4 CTNNB1 PIK3CA NLRP3 FAN1 PIGA IGH TWNK KIT TICAM1 PROP1 RPS15A NR3C1 TPO XPA PRKAR1A BMPR1A ERCC3 TET2 KIF23 TBK1 TSHB MC2R MEN1 ATP13A2 TK2 CDC73 IL10 IL12B TET2 RPL18 STAT4 MMADHC POU2AF1 FIG4 STAT3 ARMC5 VPS13A MPL PRPH TSR2 NNT HNF4A TP53 CDH23 COL5A1 BTNL2 GLI2 PTPN22 PAX8 FOXA2 CHCHD10 PTPN3 TMEM127 CD79B GATA2 IL12A MLH1 TBK1 ADA2 SRSF2 SLC12A3 IGH KRAS ARNT2 IYD TG SLC3A1 PHKG2 SMAD3 PDE11A COL1A1 ANG VAPB SLC40A1 NLRP3 OTX2 NR3C1 RPL35 HELLPAR MAX KIF1B FGF23 TCF3 PIEZO1 PIK3R1 AIP PHKA2 SDHA OTX2 HLA-DRB1 SLC25A26 TNXB CDH23 RPS19 CD46 BTK SLC4A1 SYNJ1 FTL TNFSF15 SCNN1G VHL USP8 TET2 TET2 JAK2 HBA2
Protein Mutations 3
T25W V158M V18M
SNP 0